Developing anti-infective strategies to prevent medical device infections
Massachusetts-based stealth mode biotechnology company focused on developing anti-infective strategies
Novel materials and coatings for indwelling medical devices
Winning the evolutionary arms race with effective antibiotics
Expanding the anti-infective armamentarium with AI-assisted R&D
Developing novel microbial resistant biomaterials and coatings for medical devices
Leveraging the awesome power of AI to create novel and effective antibiotics
Focus on microbial infections
Catheter-related bloodstream infection (market central lines, urinary catheters)~$2.5 billion in 2023 projected to reach ~$2.65 billion by 2034.
(Target Undisclosed): $18.4 billion (2024 est) market opportunity across all indications expected to grow to US$ 25.2B by 2033.
Interested in partnership or investment opportunities? Reach out to our team